NCT06128993 Trans-coronary Cooling and Dilution for Cardioprotection During Revascularisation for ST-elevation Myocardial Infarction
| NCT ID | NCT06128993 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust |
| Condition | Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2025-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-11-01 with a primary completion date of 2025-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A heart attack (myocardial infarction) occurs when an artery supplying blood to the heart is suddenly blocked resulting in damage to the heart muscle. Patients presenting to hospital with a heart attack undergo an immediate angiogram (x-ray of the arteries in the heart) and are usually treated immediately with a balloon and stent to open their blocked artery. This procedure is called "primary percutaneous coronary intervention" (or primary PCI for short). An angiogram is a routine procedure that involves insertion of fine plastic tube (catheter) into either the groin or wrist under local anaesthetic. The tube is passed into the artery in the heart and X-ray pictures are taken to find out if the arteries are blocked. Blocked arteries can usually be opened by passing a small balloon into the artery, via the fine plastic tube followed by placement of a stent (a fine metal coil) into the artery to prevent it from blocking again. Although this treatment is very successful, it can result in damage to the heart muscle when the artery is opened. Cooling the entire body has been shown to reduce heart muscle damage during heart attacks in some patients but not in others; however, it is uncomfortable due to the shivering, expensive and can result in delays in opening the blocked artery. The investigators are conducting a series of research studies to find out if cooling the heart muscle directly through the catheter being used for the normal primary angioplasty treatment using room temperature may be effective in preserving heart muscle, without the shortcomings of entire body cooling. The investigators have already published an initial series of ten cases in which this treatment appeared to be feasible without causing significant clinical problems. The present study is a pilot study designed to assess the rate of patient recruitment and feasibility of this new treatment while exploring some detailed outcomes measuring the restoration of blood flow within the coronary artery at the end of the procedure. Ultimately if the present pilot study is successful, the investigators plan to go on to undertake a much larger randomised outcome study to determine definitively whether this treatment can help reduce heart attack size.
Eligibility Criteria
Inclusion Criteria: * Clinical ST-elevation myocardial infarction or equivalent (e.g. new onset LBBB) * \<12 Hrs after symptom onset * Thrombolysis in myocardial infarction (TIMI) 0-1 coronary flow in a target vessel Exclusion Criteria: * History of severe asthma * Pregnancy * Severe concomitant disease or conditions with a life expectancy of less than one year.
Contact & Investigator
Miles C Dalby, MD
PRINCIPAL INVESTIGATOR
Royal Brompton & Harefield NHS Foundation Trust
Frequently Asked Questions
Who can join the NCT06128993 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06128993 currently recruiting?
Yes, NCT06128993 is actively recruiting participants. Contact the research team at m.dalby@rbht.nhs.uk for enrollment information.
Where is the NCT06128993 trial being conducted?
This trial is being conducted at Uxbridge, United Kingdom.
Who is sponsoring the NCT06128993 clinical trial?
NCT06128993 is sponsored by Royal Brompton & Harefield NHS Foundation Trust. The principal investigator is Miles C Dalby, MD at Royal Brompton & Harefield NHS Foundation Trust. The trial plans to enroll 60 participants.